Is Receptor Heterogeneity Relevant to the Anxiolytic Actions of Benzodiazepine Receptor Ligands?

  • P. Skolnick


The presence of saturable, stereoselective recognition sites for benzodiazepines (BDZ) in the central nervous system (Squires and Braestrup, 1977; Mohler and Okada, 1977) provided the stimulus to synthesize and evaluate potential anxiolytics devoid of the myorelaxant and hypnotic properties associated with ‘classical’ 1,4-BDZ. During the past decade, more than half a dozen chemically distinct (that is, unrelated to 1,4-BDZ) structures have been reported to bind with high affinities to these BDZ receptors (BDZR), with at least as many compounds reported to possess anticonflict (and/or anxiolytic) actions devoid of significant hypnotic and/or myorelaxant potential (reviewed in Skolnick and Paul, 1988). Even so, the mechanism(s) by which a BDZR ligand can effect a selective anxiolytic action has not been well defined either on a molecular or neuroanatomical level. This chapter will critically review the relationship of receptor heterogeneity to the putative ‘anxioselective’ actions of BDZR ligands.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arbilla, S., Allen, J., Wick, A. and Langer, S. (1986). High affinity [3H]zolpidem binding in the rat brain: an imidazopyridine with agonist properties at central benzodiazepine receptors. Eur. J. Pharmacol., 130, 257–63.PubMedCrossRefGoogle Scholar
  2. Arbilla, S., Depoortere, H., George, P. and Langer, S. (1985). Pharmacological profile of the imidazopyridine Zolpidem at benzodiazepine receptors and electro-corticogram in rats. Naunyn-Schmiedeberg’s Arch. Pharmacol., 330, 248–51.CrossRefGoogle Scholar
  3. Benavides, J., Malgouris, C., Flamier, A., Tur, C., Quarteronet, D., Begassat, F., Camelin, J., Uzan, A., Gueremy, C. and LeFur, G. (1984). Biochemical evidence that 2-phenyl-4[2-(4-piperidinyl)ethyl]quinoline, a quinoline derivative with pure anticonflict properties, is a partial agonist of benzodiazepine receptors. Neuropharmacol., 23, 1129–36.CrossRefGoogle Scholar
  4. Bennett, D., Amrick, C., Wilson, D., Boast, C., Loo, P., Bernard, P., Schmutz, M., Gerhardt, S., Braunwalder, A., Klebs, K., Yokoyama, N. and Liebman, J. (1987). Pharmacological characterization of CGS 17867A as a benzodiazepine receptor agonist devoid of limiting behavioural effects. Drug. Dev. Res., 11, 219–33.CrossRefGoogle Scholar
  5. Bennett, D., Amrick, C., Wilson, W., Bernard, P., Yokoyama, N. and Liebman, J. (1985). Behavioural pharmacological profile of CGS 9895: a novel anxiomodu-lator with selective benzodiazepine agonist and antagonist properties. Drug. Dev. Res., 6, 313–25.CrossRefGoogle Scholar
  6. Bennett, D. and Petrack, B. (1984). CGS 9896: a non-benzodiazepine, nonsedating potential anxiolytic. Drug. Dev. Res., 4, 75–82.CrossRefGoogle Scholar
  7. Braestrup, C., Honore, T., Nielsen, M., Petersen, E. and Jensen, L. (1984). Ligands for benzodiazepine receptors with positive and negative efficacy. Biochem. Pharmacol., 33, 859–62.PubMedCrossRefGoogle Scholar
  8. Braestrup, C. and Squires, R. (1978). Pharmacological characterization of benzodiazepine receptors in the brain. Eur. J. Pharmacol., 48, 263–70.PubMedCrossRefGoogle Scholar
  9. Braestrup, C., Schmiechen, R., Neef, G., Nielsen, M. and Petersen, E. (1982). Interaction of convulsive ligands with benzodiazepine receptors. Science, 216, 1241–3.PubMedCrossRefGoogle Scholar
  10. Braestrup, C. and Nielsen, M. (1986). Benzodiazepine receptor binding in vivo and efficacy. In Olsen, R. and Venter, C. (eds.), Benzodiazepine/GABA Receptors and Chloride Channels, Liss, New York, 167–84.Google Scholar
  11. Bristow, D. and Martin, I. (1989). GABA preincubation of rat brain sections increases [3H]GABA binding to the GABAA receptor and compromises the modulatory interactions. Eur. J. Pharmacol., 173, 65–73.PubMedCrossRefGoogle Scholar
  12. Brown, C. and Martin, I. (1985). Modification of pyrazoloquinolinone affinity by GABA predicts efficacy at the benzodiazepine receptor. Eur. J. Pharmacol., 106, 167–73.CrossRefGoogle Scholar
  13. Chan, C. and Farb, D. (1985). Modulation of neurotransmitter action: control of the γ-aminobutyric acid response through the benzodiazepine receptor. J. Neurosci., 5, 2365–72.PubMedGoogle Scholar
  14. Chweh, A. Y., Lin, Y. and Swinyard, E. (1984). Hypnotic action of benzodiazepines: a possible mechanism. Life Sci., 34, 1763–8.PubMedCrossRefGoogle Scholar
  15. Depoortere, H., Zivkovic, B., Lloyd, K., Sanger, D., Perrault, G., Langer, S. and Bartholini, G. (1986). Zolpidem, a novel nonbenzodiazepine hypnotic. I: Neuropharmacological and behavioral effects. J. Pharmacol. Exp. Ther., 237, 649–58.PubMedGoogle Scholar
  16. Ehlert, F., Roeske, W., Gee, K. and Yamamura, H. (1983). An allosteric model for benzodiazepine receptor function. Biochem. Pharmacol., 32, 2375–83.PubMedCrossRefGoogle Scholar
  17. File, S., Pellow, S. and Wilks, S. (1985). The sedative effects of CL 218,872, like those of chlordiazepoxide, are reversed by benzodiazepine antagonists. Psychopharm., 85, 295–9.CrossRefGoogle Scholar
  18. Gallagher, D., Lakoski, J., Gonsalves, S. and Rauch, S. (1984). Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature, 308, 74–7.CrossRefGoogle Scholar
  19. Gardner, C. (1985). Distress vocalization in rat pups. A simple screening method for anxiolytic drugs. J. Pharmacol. Meth., 14, 181–7.CrossRefGoogle Scholar
  20. Gardner, C. (1988). Functional in vivo correlates of the benzodiazepine agonist—antagonist continuum. Prog. in Neurobiol., 31, 425–76.CrossRefGoogle Scholar
  21. Gee, K., Brinton, R. and Yamamura, H. (1983a). CL 218872 antagonism of diazepam-induced loss of righting reflex: evidence for partial agonistic activity at the benzodiazepine receptor. Life Sci., 32, 1037–49.PubMedCrossRefGoogle Scholar
  22. Gee, K., Brinton, R. and Yamamura, H. (1983b). PK 8165 and PK 9084, two quinoline derivatives with anxiolytic properties, antagonize the anticonvulsant effects of diazepam. Brain Res., 264, 168–72.PubMedCrossRefGoogle Scholar
  23. Haefely, W. and Polc, P. (1986). Physiology of GABA enhancement by benzodiazepines and barbiturates. In Olsen, R. and Venter, C. (eds.), Benzodiazepine/GABA Receptors and Chloride Channels, Liss, New York, 97–133.Google Scholar
  24. Havoundjian, H., Paul, S. M. and Skolnick, P. (1986). The permeability of γ-aminobutyric acid-gated chloride channels is described by the binding of a ‘cage’ convulsant, t-butylbicyclophosphoro[35S]-thionate. Proc. Natl. Acad. Sci., 83, 9241–4.PubMedCentralPubMedCrossRefGoogle Scholar
  25. Karobath, M. and Sperk, G. (1979). Stimulation of benzodiazepine receptor binding by γ-aminobutyric acid. Proc. Natl. Acad. Sci. USA, 76, 1004–6.PubMedCentralPubMedCrossRefGoogle Scholar
  26. King, R., Nielsen, M., Stauber, G. and Olsen, R. (1987). Convulsant/barbiturate activity on the soluble γ-aminobutyric acid-benzodiazepine receptor complex. Eur. J. Biochem., 169, 555–62.PubMedCrossRefGoogle Scholar
  27. Klepner, C. A., Lippa, A. S., Benson, D., Sano, M. C. and Beer, B. (1979). Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors. Pharm. Biochem. and Behav., 11, 457–62.CrossRefGoogle Scholar
  28. LeFur, G., Mizoule, J., Burgevin, M., Ferris, O., Heaulme, M., Gauthier, A., Gueremy, C. and Uzan, A. (1981). Multiple benzodiazepine receptors: evidence for a dissociation between anticonflict and anticonvulsant properties by PK 8165 and PK 9084 (two quinoline derivatives). Life Sci., 28, 1439–48.CrossRefGoogle Scholar
  29. Levitan, E., Schofield, P., Burt, D., Rhee, L., Wisden, W., Kohler, M., Fujita, N., Rodriguez, H., Stephenson, A., Darlison, M., Barnard, E. and Seeburg, H. (1988). Structural and functional basis for GABAA receptor heterogeneity. Nature, 335, 76–9.PubMedCrossRefGoogle Scholar
  30. Lippa, A., Jackson, D., Wennogle, L., Beer, B. and Myerson, L. (1982a). Non-benzodiazepine agonists for benzodiazepine receptors. In Usdin, E., Skolnick, P., Tallman, J., Greenblatt, D. and Paul, S. (eds), Pharmacology of Benzodiazepines, Macmillan, London, 431–40.Google Scholar
  31. Lippa, A., Beer, B. and Myerson, L. (1982b). Neuronal substrates of anxiety: clues from the heterogeneity of benzodiazepine receptors. Life Sci., 31, 1409–17.PubMedCrossRefGoogle Scholar
  32. Lippa, A. S., Coupet, J., Greenblatt, E. N., Klepner, C. A. and Beer, B. (1979a). A synthetic non-benzodiazepine ligand for benzodiazepine receptors: A probe for investigating neuronal substrates of anxiety. Pharm., Biochem. and Behav., 11, 99–106.CrossRefGoogle Scholar
  33. Lippa, A., Critchett, D., Sano, M., Klepner, C., Greenblatt, E., Coupet, J. and Beer, B. (1979b). Benzodiazepine receptors: cellular and behavioral characteristics. Pharmacol. Biochem. and Behav., 10, 831–83.CrossRefGoogle Scholar
  34. Lippa, A., Klepner, C., Benson, D., Critchett, D., Sano, M. and Beer, B. (1980). The role of GABA in mediating the anticonvulsant properties of benzodiazepines. Brain. Res. Bull., 5, 861–5.CrossRefGoogle Scholar
  35. Lolait, S., O’Carroll, A., Kusano, K., Muller, J., Brownstein, M. and Mahan, L. (1989). Cloning and expression of a novel rat GABAA receptor. FEBS Letts., 246, 145–8.CrossRefGoogle Scholar
  36. Mackerer, C., Kochman, R., Bierschenk, B. and Bremner, S. (1978). The binding of 3H-diazepam to rat brain homogenates. J. Pharmacol. Exp. Ther., 206, 405–13.PubMedGoogle Scholar
  37. Malherbe, P., Sigel, E., Baur, R., Persohn, E., Richards, J. and Mohler, H. (1990). Functional expression and sites of gene transcription of a novel α subunit of the GABAA receptor in rat brain. FEBS Letts., 260, 261–5.CrossRefGoogle Scholar
  38. Mamalaki, C., Barnard, E. and Stephenson, F. (1989). Molecular size of the γ-aminobutyric acidA receptor purified from mammalian cerebral cortex. J. Neurochem., 52, 124–34.PubMedCrossRefGoogle Scholar
  39. McCabe, R., Olsen, R., Yezuita, J. and Wamsley, J. (1988). Osmotic shock: a method to eliminate endogenous γ-aminobutyric acid and account for the influence on benzodiazepine binding affinity in autoradiographic studies. J. Pharmacol. Exp. Ther., 245, 342–9.PubMedGoogle Scholar
  40. Mohler, H. and Richards, J. (1981). Agonist and antagonist benzodiazepine receptor interaction in vitro. Nature, 294, 763–5.CrossRefGoogle Scholar
  41. Mohler, H., Battersby, M. and Richards, J. (1980). Benzodiazepine receptor protein identified and visualized by a photoaffinity label. Proc. Natl Acad. Sci. USA, 77, 1666–70.PubMedCentralPubMedCrossRefGoogle Scholar
  42. Mohler, H. and Okada, T. (1977). Benzodiazepine receptor: demonstration in the central nervous system. Science, 198, 849–51.PubMedCrossRefGoogle Scholar
  43. Mohler, H., Okada, T., Heitz, P. and Ulrich, J. (1978). Biochemical identification of the site of action of benzodiazepines in human brain by 3H-diazepam binding. Life Sci., 22, 985–96.PubMedCrossRefGoogle Scholar
  44. Nielsen, M., Honore, T. and Braestrup, C. (1985). Radiation inactivation of brain [35S]t-butylbicyclophosphorothionate binding sites reveals complicated molecular arrangements of the GABA/benzodiazepine receptor chloride channel complex. Biochem. Pharmacol., 34, 3633–42.PubMedCrossRefGoogle Scholar
  45. Oakley, N. R., Jones, B. J. and Straughan, D. W. (1984). The benzodiazepine receptor ligand CL 218,872 has both anxiolytic and sedative properties in rodents. Neuropharmacol., 23, 797–802.CrossRefGoogle Scholar
  46. Olsen, R. and Towbin, A. (1990). Molecular biology of GABAA receptors. FASEB J., 4, 1469–80.PubMedGoogle Scholar
  47. Pellow, S. and File, S. (1986). Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. and Behav., 24, 525–29.CrossRefGoogle Scholar
  48. Petrack, B., Czernick, A., Cassidy, J., Bernard, P. and Yokoyama, N. (1983). Benzodiazepine receptor ligands with opposing pharmacologic actions. Adv. Biochem. Psychopharm., 38, 129–37.Google Scholar
  49. Pritchett, D., Luddens, H. and Seeburg, P. (1989a). Type I and Type II GABAA-benzodiazepine receptors produced in transfected cells. Science, 245, 1389–92.PubMedCrossRefGoogle Scholar
  50. Pritchett, D., Sontheimer, H., Gorman, C., Kettenman, H., Seeburg, P. and Schofield, P. (1988). Transient expression shows ligand gating and allosteric potentiation of GABAA receptor subunits. Science, 242, 1306–8.PubMedCrossRefGoogle Scholar
  51. Pritchett, D., Sontheimer, H., Shivers, B., Ymer, S., Kettenmann, H., Schofield, P. and Seeburg, P. (1989b). Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. Nature, 338, 582–5.PubMedCrossRefGoogle Scholar
  52. Ray, J., Mernoff, S., Sangameswaran, L. and DeBlas, A. (1985). The Stokes radius of the CHAPS-solubilized benzodiazepine receptor complex. Neurochem. Res., 10, 1221–9.PubMedCrossRefGoogle Scholar
  53. Schofield, P. (1989). The GABAA receptor: molecular biology reveals a complex picture. Trends Pharmacol. Sci., 10, 476–8.PubMedCrossRefGoogle Scholar
  54. Schofield, P. R., Darlison, M. G., Fujita, N., Burt, D. R., Stephenson, F. A., Rodriguez, H., Rhee, L. M., Ramachandran, J., Reale, V., Glencorse, T. A., Seeburg, P. H. and Barnard, E. A. (1987). Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family. Nature, 328, 221–7.PubMedCrossRefGoogle Scholar
  55. Schofield, P., Pritchett, D., Sontheimer, H., Kettenmann, H. and Seeburg, P. (1989). Sequence and expression of human GABAA receptor α1 and β1 subunits. FEBS Letts., 244, 361–4.CrossRefGoogle Scholar
  56. Shivers, B., Killisch, I., Sprengel, R., Sontheimer, H., Kohler, H., Schofield, P. and Seeburg, P. (1989). Two novel GABAA receptor subunits exist in distinct neuronal subpopulations. Neuron, 7, 327–37.CrossRefGoogle Scholar
  57. Sieghart, W. and Karobath, M. (1980). Molecular heterogeneity of benzodiazepine receptors. Nature, 286, 285–7.PubMedCrossRefGoogle Scholar
  58. Sieghart, W. (1989). Multiplicity of GABAA-benzodiazepine receptors. Trends in Pharmacol. Sci., 10, 407–11.CrossRefGoogle Scholar
  59. Sieghart, W. and Mohler, H. (1982). 3H-Clonazepam, like 3H-flunitrazepam, is a photoaffinity label for the central type of benzodiazepine receptors. Eur. J. Pharmacol., 81, 171–3.PubMedCrossRefGoogle Scholar
  60. Skerritt, J. and Macdonald, R. (1984). Benzodiazepine receptor ligand actions on GABA responses. Benzodiazepines, CL 218,872, zopiclone. Eur. J. Pharmacol., 101, 127–34.PubMedCrossRefGoogle Scholar
  61. Skolnick, P. and Paul, S. (1988). Nonbenzodiazepine ligands of the benzodiazepine receptor. In Squires, R. (ed.), GABA and Benzodiazepine Receptors, Vol. II, CRC Press, Boca Raton, Fla., 91–102.Google Scholar
  62. Skolnick, P., Schweri, M., Williams, E., Moncada, V. and Paul, S. (1982). An in vitro test which differentiates benzodiazepine ‘agonists’ and ‘antagonists’. Eur. J. Pharmacol., 78, 133–6.PubMedCrossRefGoogle Scholar
  63. Squires, R. F., Benson, D. I., Braestrup, C., Coupet, J., Kiepner, C. A., Myers, V. and Beer, B. (1979). Some properties of brain specific benzodiazepine receptors: New evidence for multiple receptors. Pharm. Biochem. and Behav., 10, 825–30.CrossRefGoogle Scholar
  64. Squires, R. and Braestrup, C. (1977). Benzodiazepine receptors in rat brain. Nature, 266, 732–4.PubMedCrossRefGoogle Scholar
  65. Squires, R., Casida, J., Richardson, M. and Saederup, E. (1983). [35S]t-Butylbicyclophosphorothionate binds with high affinity to brain specific sites coupled to γ-aminobutyric acid-A and ion recognition sites. Mol. Pharmacol., 23, 326–36.PubMedGoogle Scholar
  66. Weber, K., Kuhn, F., Boke-Kuhn, K., Lehr, E., Dannenberg, P., Hommer, D., Paul, S. and Skolnick, P. (1985). Pharmacological and neurochemical properties of 1,4-diazepines with two annelated heterocycles (‘hetrazepines’). Eur. J. Pharmacol., 109, 19–31.PubMedCrossRefGoogle Scholar
  67. Wood, P., Loo, P., Braunwalder, A., Yokoyama, N. and Cheney, D. (1984). In vitro characterization of benzodiazepine receptor agonists, antagonists, inverse agonists and agonist/antagonists. J. Pharmacol. Exp. Ther., 231, 572–6.PubMedGoogle Scholar
  68. Yamamura, H., Mimaki, T., Yamamura, S., Horst, W., Morelli, M., Bautz, G. and O’Brien, R. (1982). [3H]CL 218,872, a novel triazolopyridazpine which labels the benzodiazepine receptor in rat brain. Eur. J. Pharmacol., 77, 351–7.PubMedCrossRefGoogle Scholar
  69. Ymer, S., Schofield, P., Draguhn, A., Werner, P., Kohler, M. and Seeburg, P. (1989). GABAA receptor β subunit heterogeneity: functional expression of cloned cDNAs. EMBO J., 8, 1665–70.PubMedCentralPubMedGoogle Scholar

Copyright information

© Macmillan Publishers Limited 1991

Authors and Affiliations

  • P. Skolnick
    • 1
  1. 1.Laboratory of Neuroscience NIDDKNational Institute of HealthBethesdaUSA

Personalised recommendations